
SAN FRANCISCO-Many signaling cascade proteins, such as Ras, that lead to cancerous changes require an isoprenyl moiety attached by farnesyl transferase for activity. Farnesyl transferase inhibitors (FTI) are under study as a possible way to derail cancer progression. Three early studies of one such compound, R115777, show that it has promise against breast, colorectal, and other solid tumors. Janssen Research Foundation of Titusville, New Jersey, sponsored all three studies.
